As drug candidates discovered via AI move into later-stage clinical trials, the technology seems to be doing as promised: ...

For biotech companies the past two years have been challenging. Biotech investments have not reached the record levels of ...

A new analysis of drug trials used to approve medicines in the United States shows how far modern medicine still has to go to ...

Rare disease clinical trials are smaller and often use surrogate endpoints, reducing costs but posing unique operational ...

Estimating the probability of success in clinical trials is a key factor influencing the decision to fund a development programme for a therapeutic candidate. A higher likelihood of approval increases ...

The pipeline of anti-obesity medications (AOMs) is rapidly expanding, with more than 170 assets in development 1 — a surge driven by the success of incretin mimetics like semaglutide and tirzepatide. ...

Together with robust data-driven modeling, rethinking regulation and data use could push forward a notoriously challenging ...

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

As drug costs rise and public trust falls, A.I. may transform the economics of clinical trials—and reshape the future of pharma. Unsplash+ Sixty percent of the total U.S. population takes at least one ...

Transfection is a crucial non-viral technique for introducing DNA or RNA into cells, yet achieving high efficiency and consistency can be challenging, particularly with difficult cell types.

Developing high-quality, safe, and effective drugs is a complex process that requires varied scientific skills and stringent regulatory assessments. Drug development is a process that spans many years ...